ABSTRACT
10.3969/j.issn.2095-4344.2013.23.023
ABSTRACT
10.3969/j.issn.2095-4344.2013.23.025
ABSTRACT
10.3969/j.issn.2095-4344.2013.23.017
ABSTRACT
10.3969/j.issn.2095-4344.2013.23.018
ABSTRACT
10.3969/j.issn.2095-4344.2013.23.020
ABSTRACT
10.3969/j.issn.2095-4344.2013.23.021
ABSTRACT
10.3969/j.issn.2095-4344.2013.23.024
ABSTRACT
BACKGROUND:Induced pluripotent stem cel s can bypass the ethical issues of embryonic stem cel s, and become the hotspot of stem cel research. OBJECTIVE:To explore the research progress and problems of induced pluripotent stem cel s. METHODS:A retrospective analysis on the findings, research progress and problems of induced pluripotent stem cel s in recent years was performed. The Thomson Reuters Web of Science was searched for the articles related to the induced pluripotent stem cel s and p53 gene. RESULTS AND CONCLUSION:In recent years, domestic and foreign scholars have conducted a lot of researches on induced pluripotent stem cel s. For example, a Japanese group is establishing the stem cel bank to provide a basis for the treatment of retinal diseases. However, the safety issues of induced pluripotent stem cel s need to be solved before routine cel treatment application, in which the functional research of related p53 gene is one of the essential concerns. The other member of p53 gene, p73 gene, also participates in the generation and differentiation of induced pluripotent stem cel s, and the in-depth studies are needed. The finding of p53 gene function wil promote the in-depth development of regenerative medicine and translational medicine.
ABSTRACT
BACKGROUND:The stem cel s transplanted into the damaged heart tissues can differentiate into cardiomyocytes, which bring new hope for the research of ischemic heart disease. OBJECTIVE:To explore the feasibility and safety of stem cel transplantation for the treatment of ischemic heart disease. METHODS:Various experimental methods to the feasibility and safety of stem cel transplantation for the treatment of ischemic heart disease were analyzed. REPAIR-AMI experiment was a randomized and double-blind and placebo-control ed multi-center study that used to analyze the therapeutic effect of intracoronary transplantation of bone marrow progenitor cel s immediately after acute myocardial infarction. MAGIC Cel-3-DES experiment was used to evaluate the safety of granulocyte colony-stimulating factor mobilized stem cel therapy and the effect of intracoronary injection of mobilized peripheral blood stem cel s on the treatment of acute myocardial infarction and old myocardial infarction. BOOST experiment was the randomized control ed study on autologous bone marrow cel transplantation through coronary vein after myocardial infarction. PROTECT-CAD experiment was the randomized control ed clinical trial about the direct injection of stem cel s into the myocardial for the treatment of ischemic heart disease. RESUTLS AND CONCLUSION:Stem cel transplantation may improve the left ventricular systolic function and left ventricular diastolic function as wel as the coronary flow reserve, and the related studies have been confirmed. Stem cel transplantation for the treatment of ischemic heart disease can increase the left ventricular ejection fraction. As the less clinical accident, stem cel therapy cannot increase the risk of restenosis based on the treatment of drug-eluting stents. It is safe and feasible of stem cel transplantation for the treatment of ischemic heart disease. Large sample, long scale and multi-center randomized control ed studies are needed to further evaluate the effect and risk of stem cel transplantation.
ABSTRACT
BACKGROUND:Umbilical cord blood as a source of hematopoietic stem cel s has become a hot topic. Adjuvant therapy of umbilical cord blood transfusion has been used in China to correct renal anemia of uremia patients. OBJECTIVE:To evaluate the efficacy and safety of umbilical cord blood mesenchymal stem cel s in the treatment of renal anemia, and to compare with the effects of different sources of mesenchymal stem cel s with different transplantation methods on the treatment of kidney diseases. METHODS:A retrospective analysis was conducted on six renal anemia patients in the Department of Outpatient, Henan Red Cross Blood Center between January 2010 and December 2012. The experiment was approved by Medical Ethics Committee, six patients were informed consent for treatment programs, and parturients and their families have signed the informed consent. The newborns umbilical cord blood of 80-140 mL were col ected with closed sterile plastic blood bags, and then the separated umbilical cord blood mesenchymal stem cel s were transfused into the renal anemia patients through the superficial vein in the back of the hand with the number of≥1×108/copy, two copies per time, and re-transfused after 4 days, a total of three times. The blood hematocrit, hemoglobin, red blood cel s in urine, renal blood flow changes were observed before and after treatment. RESULTS AND CONCLUSION:The hemoglobin, blood hematocrit, red blood cel s in urine and renal blood flow were significantly increased before and after treatment (P<0.05). Transfusion of multiple copies of umbilical cord blood mesenchymal stem cel s through the superficial vein in the back of the hand is convenient and safe, which is considered as a new method for the treatment of renal anemia. But there are certain limitation in the data and the conclusion as the clinical research was designed as self-control, so further confirm is needed.